ISSN:
1432-0843
Keywords:
Key words Treosulfan
;
Dihydroxybusulfan
;
Pharmacokinetics
;
Infusion
;
Patient
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Abstract Treosulfan (l-threitol-1,4-bis-methanesulfonate, Ovastat) is a prodrug of a bifunctional alkylating agent with activity in ovarian carcinoma and other solid tumors. For a clinical and pharmacology study, patients with advanced, refractory, or resistant solid tumors were treated with a single-dose intravenous 30-min infusion of 8 or 10 g/m2 treosulfan. A sensitive method for the determination of treosulfan in plasma and urine by reverse-phase high-performance liquid chromatography was developed. A total of 14 plasma and urine treosulfan pharmacokinetics determinations were analyzed in the 8-g/m2 group and 7 were analyzed in the 10-g/m2 group, the maximum tolerated dose for this group of pretreated patients. The terminal half-life of treosulfan was in the range of 1.8 h. AUC and Cmax values were significantly (P 〈 0.01) higher in the 10-g/m2 group (AUC 708 ± 168 versus 977 ± 182 μg ml−1 h, Cmax 465 ± 98 versus 597 ± 94 μg/ml). The mean urinary excretion of the parent compound was about 25% of the total dose delivered over 48 h (range 5–49%), and about 20% was excreted during the first 6 h after administration. Currently, a clinical phase I pharmacokinetics and dose-escalation trial with autologous blood stem-cell support has been started at 20 g/m2 treosulfan using a 2-h infusion protocol.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/s002800050791
